UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rational combination of cancer immunotherapy in melanoma

Virchows Archiv : an international journal of pathology, 2019-04, Vol.474 (4), p.433-447

2019

Volltextzugriff (PDF)

Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

European journal of cancer (1990), 2021-05, Vol.148, p.371-381

2021

Volltextzugriff (PDF)

Treatment of venous thromboembolism in cancer patients: The dark side of the moon

Cancer treatment reviews, 2021-05, Vol.96, p.102190-102190, Article 102190

2021

Volltextzugriff (PDF)

Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

Current oncology reports, 2018-11, Vol.20 (11), p.86-16, Article 86

2018

Volltextzugriff (PDF)

Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis

Cancer treatment reviews, 2021-11, Vol.100, p.102280-102280, Article 102280

2021

Volltextzugriff (PDF)

New Therapies in Advanced Cutaneous Malignancies

1st Edition 2021, 2021

Volltextzugriff (PDF)

Differential HLA class I subunit (A, B, C heavy chain and β2-microglobulin) expression levels in normal tissues

Virchows Archiv : an international journal of pathology, 2023-02, Vol.482 (2), p.359-368

2023

Volltextzugriff (PDF)

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-01, Vol.25 (1), p.197-206

2022

Volltextzugriff (PDF)

Mechanisms of Drug Resistance in Cancer Therapy

1st ed. 2018., 2019

Volltextzugriff (PDF)

Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

Journal of translational medicine, 2011-10, Vol.9 (1), p.179-179, Article 179

2011

Volltextzugriff (PDF)

Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications

Biomedicines, 2021-05, Vol.9 (6), p.607

2021

Volltextzugriff (PDF)

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

BMC cancer, 2019-08, Vol.19 (1), p.772-10, Article 772

2019

Volltextzugriff (PDF)

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

European journal of cancer (1990), 2024-03, Vol.200, p.113587-113587, Article 113587

2024

Volltextzugriff (PDF)

Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management

Thrombosis research, 2010-04, Vol.125, p.S117-S119

2010

Volltextzugriff (PDF)

Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al

Journal for immunotherapy of cancer, 2022-01, Vol.10 (1), p.e004347

2022

Volltextzugriff (PDF)

The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022

Journal of translational medicine, 2023-04, Vol.21 (1), p.265-14, Article 265

2023

Volltextzugriff (PDF)

The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors

Journal for immunotherapy of cancer, 2019-11, Vol.7 (1), p.308-308, Article 308

2019

Volltextzugriff (PDF)

Prevalence and Clinical Impact of SARS‐CoV‐2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID‐19 Pandemic

The oncologist (Dayton, Ohio), 2021-04, Vol.26 (4), p.341-347

2021

Volltextzugriff (PDF)

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Journal for immunotherapy of cancer, 2020-11, Vol.8 (2), p.e001117

2020

Volltextzugriff (PDF)

Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective

Nutrition & metabolism, 2019-05, Vol.16 (1), p.33-33, Article 33

2019

Volltextzugriff (PDF)

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

Journal for immunotherapy of cancer, 2021-02, Vol.9 (2), p.e001694

2021

Volltextzugriff (PDF)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Journal for immunotherapy of cancer, 2021-01, Vol.9 (1), p.e001931

2021

Volltextzugriff (PDF)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e003188

2021

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

ThemaCancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(53)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Rational combination of cancer immunotherapy in melanoma

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

Treatment of venous thromboembolism in cancer patients: The dark side of the moon

Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis

New Therapies in Advanced Cutaneous Malignancies

Differential HLA class I subunit (A, B, C heavy chain and β2-microglobulin) expression levels in normal tissues

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Mechanisms of Drug Resistance in Cancer Therapy

Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial

Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management

Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al

The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022

The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors

Prevalence and Clinical Impact of SARS‐CoV‐2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID‐19 Pandemic

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Aktive Filter

Suchergebnisse filtern